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Summary Several studies have focused on the role of p53 inactivation in cervical cancer, either by inactivating mutations in the TP53 gene
or by degradation of the p53 protein by human papillomavirus (HPV). In this study, primary cervical carcinomas from 365 patients were
analysed for presence of HPV using both consensus primer-sets and type-specific primer-sets. Nineteen samples were determined to have
no or low virus load, and were selected for further analyses: mutation screening of the TP53 gene using constant denaturant gel
electrophoresis (CDGE) followed by sequencing, and protein expression of p53, MDM2 and p21 using immunohistochemistry (IHC).
Mutations in the TP53 gene were found in eight samples (42%0/). Elevated p53 protein expression was significantty associated with presence
of a mutation (P < 0.007). P21 protein expression was detected in 16 of the 19 carcinomas. No p21 expression was seen in normal cervical
tissue. Two samples, both with wild-type p53, had elevated MDM2 expression. Compared with a previous study from our group, of mainly
HPV-positive cervical carcinomas, in which only one sample was found to contain a TP53mutation, a significantly higher mutation frequency
(P< 0.001) was found among the carcinomas with no or low virus load. Although p53 inactivation pathways are not detected in every tumour,
our study supports the hypothesis that p53 inactivation, either by binding to cellular or viral proteins or by mutation, is essential in the
development of cervical carcinomas.
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Over recent years. data supporting the hypothesis that specific
types of human papillomavirus (HPV) play a central role in the
pathogenesis of cervical dysplasia and invasive cancer of the
cervix have emerged (Bosch et al. 1995). The viral E6 and E7
genes of the high-risk HPV (HPV 16 and -18) are regularly
expressed in HPV-positive tumours (Durst et al. 1992). The E6
protein of the oncogenic HPV 16 has the ability to bind p53
protein. This binding has been shown to stimulate degradation of
p53 in vitro by ubiquitin proteolysis and hence inactivate its func-
tions (Scheffner et al. 1990). This inactivation may lead to tumour
development. An important downstream target for p53 has been
identified in the P211WAFI/CIPJ gene coding for a cyclin-
dependent kinase inhibitor, and whose transcription is directly
induced by wild-type p53 (El-Deiry et al. 1993).
Studies have shown that HPV-negative cervical carcinoma cell
lines reveal mutations in the TP53 gene. whereas no such muta-
tions are present in the HPV-positive cell lines (Crook et al. 1991:
Scheffner et al. 1991: Yaginuma and Westphal. 1991: Srivastava et
al. 1992: Iwasaka et al. 1993). A hypothesis evolved that p53 can
either be inactivated by mutation or complex formation with HPV
E6 oncoprotein. However. studies on primary cervical carcinomas
have shown that TP53 mutations seem to be rare and present in
both HPV-negative and -positive tumours (B0rresen et al. 1992:
Fujita et al. 1992: Tsuda et al. 1992: Chen et al. 1993: Choo and
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Chong. 1993: Helland et al. 1993: Paquette et al. 1993: Busby-
Earle et al. 1994: Jiko et al. 1994: Ikenberg et al. 1995: Milde-
Langosch et al. 1995: Miwa et al. 1995). Hence. alternative
pathways for p53 inactivation have been discussed. MDM2 is a
negative cellular regulator of p53 protein activity (Kubbutat et al.
1997). Amplification of MDM2 could lead to p53 inactivation in
HPV-negative tumours. Recent studies have shown that MDM2
amplification is rare in primary cervical carcinoma (Ikenberg.
1995: Miwa, 1995).
From a series of 365 primary cervical carcinomas analysed for
HPV with several different primers - both consensus and type
specific - 19 tumours with no or low virus load were selected for
further analyses. These samples were analysed for TP53 mutation
by constant denaturant gel electrophoresis (CDGE) followed by
sequencing as well as immunohistochemistry to detect p53. p2l
(Waf1) and MDM2 protein expression.
MATERIALS AND METHODS
Material
Material for this study was obtained from 365 patients with
primary cervical carcinomas admitted to the Department of
Gynaecological Oncology. The Norwegian Radium Hospital. in
the period from 1988 to 1993. The HPV results of 361 of these
have previously been published (Karlsen et al. 1996). In addition.
three clear-cell carcinomas and one small-cell carcinoma were
included. DNA extraction was performed with standard methods
(phenol-chloroform extraction and ethanol precipitation).
Nineteen cases were judged negative or weak positive for HPV.
The histological types ofthese samples are shown in Table 1.
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Table 1 Clinical stage, histological diagnosis, HPV status and protein
expression of p53, MDM2 and p21 of the 19 primary cervical carcinomas with
no or low virus load
Sample Histology FIGO HPV TP53 p53 MDM2 p21
no. stage stats status- staining staining staining
wt
M
M
M
wt
M
wt
M
wt
wt
wt
wt
wt
M
M
wt
wt
wt
F698 SCC IIB Negative
F707 SCC IB Negative
H90 SCC IIIB Negative
H148 SCC IIB Negative
H261 SCC IIA Negative
H304 SCC IIB Negative
H335 SCC IIA Negative
F2231 AC IVB Negative
F783 CCC IIIB Negative
F285 CCC IB Negative
F764 CCC IB Negative
H116 SCC IIIB HPV 11
F2234 SCC IIB HPV X
F665 SCC IIIB HPV X
H146 SCC IVB HPV 16
F2678 AC IIIB HPV X
F301 AC IIIB HPV X
H98 AC IVB HPV16,
HPV 33
F763 SmCC IIB HPV X
SCC, squamous cell carcinoma; AC, adenocarcinoma; CCC, clear-cell
carcinoma; SmCC, small-cell carcinoma; wt, wild type; M, mutated TP53 -,
no protein expression detected; +, protein expressed in <5% of the cells; ++,
protein expressed in 5-50°% of the cells; ++-, protein expressed in >50%/o of
the cells; HPV X, posiive onty when using one consensus primer set. a For
type of mutation see Table 2.
Table 2 Type of mutations detected in the TP53 gene in HPV-negative/
weak positve primary cervical carcnomas
Sample Affected Affected Muttkon Amino acid
exon codon change
H146 5 181 CGC-*TGC Arg-*Cys
6 213 CGA-*TGA Arg-*stop
H148 5 175 CGC-*CAC Arg-*His
5 181 CGC-4TGC Arg-+Cys
F763 6 190/191 CCTCCT lrsertion-*
-+CCATCCT Frameshift
7 240 AGT-*CGT Ser-*Arg
H90 7 248 CGG-*CAG Arg-*Gln
F665 7 ND ND ND
H304 8 280 AGA-*ACA Arg-yThr
F707 8 281 GAC-+CAC Asp-*Ala
F2231 8 282 CGG-*TGG Arg-*Trp
ND, not detected by sequencing.
HPV detection
The primers used for PCR were the consensus primers Oli of the
LI gene (modified from Jenkins et al. 1991: Karlsen et al. 1996).
My of the LI gene (Manos et al. 1989). Gp of the LI (de Roda
Husman et al. 1995) and Cp ofthe El gene (Tieben et al. 1993). In
addition, type-specific primers were used for HPV type 11. 16. 18.
31. 33 and 35. Details of the polymerase chain reaction (PCR)
methods are described in detail elsewhere (Karlsen et al, 1996).
The My. Cp and Gp PCR products were detected by electroblot
++*
+++
+++
++
4*i
+
+
++
++
++
++
++
++
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++
++
hybridization to consensus probes. The type specific-PCR
products were submitted to polyacrylamide gel electrophoresis.
and stained with ethidium bromide or SYBR green I.
TP53 mutation analysis using CDGE
The 19 samples with no or low HPV load were analysed for muta-
tion of exons 5-8 of the TP53 gene using CDGE (Andersen and
B0rresen. 1995; B0rresen. 1996). The PCR fragments showing
altered mobility in the CDGE analyses were submitted to PCR and
directed to determine the exact nature ofthe mutation.
Immunohistochemistry
Sections from formalin-fixed. paraffin-embedded blocks were
microwaved and immunostained using the avidin-biotin--peroxi-
dase complex (ABC) method. Four semiquantitative classes were
used to describe the number of immunostained tumour cells: -.
none; +. less than 5% of the cells; ++, 5-50% of the cancer cells;
and +++. more than 50% ofthe cells.
P-values were calculated by the program Epi-Info, using two-
tailed Fisher exact test when appropriate. P-values were consid-
ered significant when less than 0.05.
RESULTS
Ofthe 365 pnrmary cervical carcinomas analysed. 354 (97%) were
found to be HPV positive. Two samples described as HPV positive
in the previous study (Karlsen et al. 1996) were not found to
contain any detectable HPV DNA by repeated analyses. From this
series, a total of 19 samples were scored as HPV negative or with
a low HPV load (Table 1). In 11 samples (3%), no HPV sequences
were detected and in eight tumours (2%) a weak signal (evaluated
visually) was repeatedly seen (Table 1).
Mutation analyses of the TP53 gene revealed mutations in 8 of
the 19 samples (42%). 5 among the 11 totally HPV negative (45%)
and three among the eight samples with a low virus load (38%).
Mutations were found in all histological types except the clear-cell
carcinomas which were all HPV negative with no mutation
detected in the TP53 gene. Sequencing results ofthe samples with
TP53 mutations are shown in Table 2. In three samples. two
different mutations were detected. One example is shown in
Figure 1.
Elevated p53 protein expression was significantly associated
with the presence of TP53 mutation (P < 0.007). Two mutated
samples showed no p53 protein expression. One of these (F763)
revealed an insertion after sequencing, leading to a frameshift and
a stop in codon 207/208. In the other tumour (F665). the mutation
was not detected by sequencing, most probably because of a muta-
tion present only in a small fraction of the cells as judged by the
CDGE analyses.
Ten cases of normal cervix obtained from hysterectomy speci-
mens were immunostained forp53. p2l/Waf- 1 and MDM2 protein
and were all scored negative. MDM2 expression was seen in two
of the cervical carcinoma samples. both with a wild-type TP53
gene. Sixteen of the 19 carcinomas showed elevated expression of
p21. The three samples with no detectable p21 protein expression
were all mutated in the TP53 gene.
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Figure 1 Mutton analyses of sample F763 with two different mutons. A and B CDGE of exon 6 and exon 7. Lane 1, F763; lane 2, normal control; lane 3,
mutan control. C and D Sequencing of exons 6 and 7 of sample F763 showing the exac nature of Fte mutabon
DISCUSSION
A low frequency of HPV-negative samples (3%) and samples
weak positive (2%) for HPV was found in this series of 365
primary cervical carcinomas. This is in agreement with the 93%
reported by Bosch et al (1995), reviewing 932 cervical carcnomas
from 22 countries using PCR methods.
In our PCR analyses, some samples produced a faint signal after
staining. This may indicate a low viral load, virus present in only a
small subpopulation of the cells or a tuncated, integrated virus
genome, which may in some instances still have been essential for
the initiation of the carcinogenesis.
HPV 16 is predominantly found, in squamous cell carcinomas,
whereas type 18 is most commonly found in adenocarcinomas of
the cervix (Bosch et al, 1995). The rare histological type clear-cell
carcinoma was diagnosed in three samples. These were all HPV
negative with no mutation in the TP53 gene. It is likely that other
mechanisms are involved in the development of these carcinomas.
The issue of TPS3 mutation and HPV infection has been inves-
tigated by several groups since the first studies on cell lines were
published. The mutation frequency vanes from 0% to 14% in
HPV-positive samples and from 0% to 50% among HPV negative
with most studies in the range 10-30%. In the present study of365
samples, 19 were HPV negative or found to have a low virus load.
Of these, eight (42%) revealed mutation in the TPS3 gene. When
omitting the clear-cell samples from the analyses, 5/8 (62.5%)
totally HPV-negative samples were found to have a TPS3 muta-
tion. This high percentage may reflect that our series of HPV-
negative samples is highly selected after thorough analyses for
presence of HPV both by consensus primers and type-specific
primers. Hence, we can assume that the HPV-negative carcinomas
are truly HPV negative. Compared with a previous study from our
group (Borresen et al, 1992, Helland et al, 1993), performed on
predominantly HPV-positive material, this series ofHPV-negative/
weak positive samples reveals a significantly higher frequency of
TP53 mutations (P < 0.001).
Three samples revealed two different TP53 mutations (Table 2).
Two of these samples (H146, H148) had a C -* T transversion in
codon 181, leading to an arginine to cystein amino acid substitu-
tion. This mutation has previously been detected as a germline
mutation in an early-onset breast cancer patient (Sidransky et al,
1992). We cannot rule out the possibility that the codon 181 alter-
ation is a rare germilne variant distributed within the normal popu-
lation. Unfortunately, no germline DNA from these two patients
was available. In addition to viral gene products, several cellular
proteins are implicated in the inactivation of p53, and could be
responsible for p53 inactivation in HPV-negative carcinomas. In
this study only two samples had elevated MDM2 expression, both
among the 11 samples with no mutation detected in the TP53 gene.
Studies on larger series analysing both MDM2 gene amplification
and protein expression are required to identify further the impor-
tance ofMDM2 in cervical carcinomas.
In this series ofHPV-negative or weakly HPV-positive cervical
carcinoma samples, TP53 mutation was found in a relatively high
percentage (42%). Only 2% ofthe samples had neither TP53 muta-
tion, HPV infection nor MDM2 overexpression, indicating that
p53 inactivation is important for the development of the majority
ofcervical carcinomas.
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